Why BIOLASE Shares Are Surging Friday
Why BIOLASE Shares Are Surging Friday
BIOLASE, Inc. (NASDAQ:BIOL) shares are surging after the company reported better-than-expected fourth-quarter FY23 EPS results.
Revenue of $13.49 million missed the consensus of $13.55 million. Gross profit stood at $3.52 million vs. $3.60 million a year ago.
EPS loss of $(1.76) was better than the consensus of $(2.56).
As of December 31, 2023, cash and cash equivalents stood at $6.57 million.
John Beaver, President and Chief Executive Officer, said, "The increased utilization of our installed base is a bullish sentiment, as evidenced by the 20% increase in our consumable sales during the year, so our goal is to accelerate growth while continuing to improve our operations."
"Greater adoption of our dental lasers, coupled with the expansion of our gross margins and lower operating expenses, will allow us to meet our revenue and profitability objectives for 2024."
Outlook: BIOLASE expects first-quarter net revenue to exceed $10.0 million vs. consensus of $10.796 million, and relatively flat Y/Y.
For FY24, the company expects net revenue to increase between 6% and 8% Y/Y to $52 million and $53 million (vs. $53.068 million estimate) and expects positive adjusted EBITDA results.
The outlook reflects the continued adoption of lasers and consumables by the dental community, including general dentists, dental specialists, dental hygienists, and group practice entities (DSOs).
Investors can gain exposure to BIOLASE via Vanguard Extended Market ETF (NYSE:VXF).
Price Action: BIOL shares are up 28% at $0.1922 on the last check Friday.
Photo via Shutterstock
BIOLASE, Inc. (NASDAQ:BIOL) shares are surging after the company reported better-than-expected fourth-quarter FY23 EPS results.
BIOLASE, Inc.（納斯達克股票代碼：BIOL）公佈的23財年第四季度每股收益好於預期後，股價飆升。
Revenue of $13.49 million missed the consensus of $13.55 million. Gross profit stood at $3.52 million vs. $3.60 million a year ago.
1,349萬美元的收入未達到共識的1,355萬美元。毛利爲352萬美元，去年同期爲360萬美元。
EPS loss of $(1.76) was better than the consensus of $(2.56).
每股收益虧損1.76美元，好於市場普遍預期的2.56美元。
As of December 31, 2023, cash and cash equivalents stood at $6.57 million.
截至2023年12月31日，現金及現金等價物爲657萬美元。
John Beaver, President and Chief Executive Officer, said, "The increased utilization of our installed base is a bullish sentiment, as evidenced by the 20% increase in our consumable sales during the year, so our goal is to accelerate growth while continuing to improve our operations."
總裁兼首席執行官約翰·比弗表示：“我們裝機群利用率的提高是一種看漲情緒，年內消費品銷售增長20％就證明了這一點，因此我們的目標是在繼續改善運營的同時加速增長。”
"Greater adoption of our dental lasers, coupled with the expansion of our gross margins and lower operating expenses, will allow us to meet our revenue and profitability objectives for 2024."
“更多地採用牙科激光器，加上毛利率的擴大和運營開支的降低，將使我們能夠實現2024年的收入和盈利目標。”
Outlook: BIOLASE expects first-quarter net revenue to exceed $10.0 million vs. consensus of $10.796 million, and relatively flat Y/Y.
展望：BIOLASE預計第一季度淨收入將超過1,000萬美元，而市場預期爲1,0796萬美元，同比相對持平。
For FY24, the company expects net revenue to increase between 6% and 8% Y/Y to $52 million and $53 million (vs. $53.068 million estimate) and expects positive adjusted EBITDA results.
該公司預計，24財年的淨收入將同比增長6％至8％，達到5200萬美元至5,300萬美元（預期爲5,3068萬美元），並預計調整後的息稅折舊攤銷前利潤業績爲正值。
The outlook reflects the continued adoption of lasers and consumables by the dental community, including general dentists, dental specialists, dental hygienists, and group practice entities (DSOs).
展望反映了包括普通牙醫、牙科專家、牙科衛生員和團體執業實體（DSO）在內的牙科界持續採用激光和消耗品。
Investors can gain exposure to BIOLASE via Vanguard Extended Market ETF (NYSE:VXF).
投資者可以通過Vanguard擴展市場ETF（紐約證券交易所代碼：VXF）獲得BIOLASE的敞口。
Price Action: BIOL shares are up 28% at $0.1922 on the last check Friday.
價格走勢：在週五的最後一次支票中，BIOL股價上漲28％，至0.1922美元。
Photo via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧